SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Elizabeth Barrett Browning

PatientElizabeth Barrett Browning
Date of birth1987-03-06
IdentifiersMRN HR-NI026-SYN; SSN (made up) 000-26-4157
Document date2026-10-19
AuthorClementine Haverford-Asante, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Seven-month review after an exacerbation: lungs, opioid therapy, mood, safety, weight, and vaccines. [S]

History of Present Illness

Ms. Barrett Browning returns seven months after diagnosis and ten weeks after an exacerbation of bronchiectasis, treated at home with amoxicillin for 14 days; the culture from that visit grew Haemophilus influenzae sensitive to amoxicillin, and she was back to her usual sputum within two weeks. She has had no blood since. She finished her sixteen grief sessions in July and had one booster session last month. She has stayed at morphine solution 4 mL twice daily since June, by her choice through the summer and the chest infection, and now asks for the next small step. She is writing every day and has gained weight. [S]

ElementDetail
ExacerbationOne in August, treated at home; recovered in two weeks
Opioid8 mg twice daily since June; asks for the next step
Grief therapySixteen sessions completed and one booster
Weight44.2 kg

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy good
RespiratoryPositiveMorning cough with about a tablespoon of sputum; no blood
GastrointestinalNegativeAppetite good; stools regular
PsychiatricNegativeMood steady; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued)5 mL (10 mg) twice daily, morning and bedtimeOral route2019-03-01 to 2026-04-19completedS
Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911As needed for suspected overdose; keep two devices at homeNasal route2026-03-16activeS
Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth dailyTwo tablets dailyOral route2026-03-16activeS
Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for 14 daysOne capsule three times daily for 14 daysOral route2026-08-10 to 2026-08-23completedS
Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day)4.5 mL (9 mg) twice daily, morning and bedtimeOral route2026-04-20 to 2026-06-14completedS
Morphine sulfate 2 mg/mL oral solution, 4 mL (8 mg) by mouth twice daily, morning and bedtime (16 mg a day)4 mL (8 mg) twice daily, morning and bedtimeOral route2026-06-15 to 2026-10-18completedS
Morphine sulfate 2 mg/mL oral solution, 3.5 mL (7 mg) by mouth twice daily, morning and bedtime (14 mg a day)3.5 mL (7 mg) twice daily, morning and bedtimeOral route2026-10-19activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-19Body height157cmS
2026-10-19Body weight44.2kgS
2026-10-19Body mass index (BMI) [Ratio]17.9kg/m2S
2026-10-19Systolic blood pressure106mm[Hg]S
2026-10-19Diastolic blood pressure68mm[Hg]S
2026-10-19Heart rate82/minS
2026-10-19Respiratory rate16/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-19C reactive protein [Mass/volume] in Serum or Plasma3.2mg/L<=5 mg/LNormalS
2026-10-19Leukocytes [#/volume] in Blood by Automated count7.410*3/uL4-11 10*3/uLNormalS
2026-10-19Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 44.2 kg, BMI 17.9
RespiratoryA few crackles at the left base; no wheeze
NeurologicalNot drowsy; pupils normal size
PsychiatricWarm and engaged; no suicidal ideation

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with daily yellow sputum, occasional streaks of blood, and breathlessness on stairs, worse in winter, for several years after an illness with blood in the sputum about eight years ago; tuberculosis, nontuberculous mycobacteria and bronchiectasis to be distinguishedresolvedconfirmed R05.3S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; it echoes her documented chest illness (D).
Non-cystic fibrosis bronchiectasis of the left lower lobe and lingula with chronic Haemophilus influenzae infection and mild airflow obstruction (Bronchiectasis Severity Index 3, mild); tuberculosis and nontuberculous mycobacterial disease excluded; synthetic modern diagnosis chosen for a historical chest illness whose cause is disputedactiveconfirmed J47.9S — Synthetic modern diagnosis; the nature of her historical chest illness remains undetermined (R, disputed).
Long-term prescribed opioid therapy (oral morphine 20 mg a day for many years, for cough, sleeplessness and palpitations), with expected physiological dependence; no opioid use disorder on DSM-5-TR assessmentactiveconfirmed Z79.891S — Synthetic modern problem anchored to her documented prescribed opium (D); tolerance and withdrawal on prescribed opioids do not count toward opioid use disorder.
Prolonged grief disorder after the drowning of her closest brother five years ago, with yearning, self-blame, avoidance of reminders of the sea, and depressive symptoms (PHQ-9 12); no suicidal ideationactiveconfirmed F43.81S — Synthetic modern diagnosis anchored to her documented bereavement (D); not a claim about her real mental health.
Vitamin D deficiency (25-hydroxyvitamin D 15 ng/mL) in a woman who rarely goes outdoorsresolvedconfirmed E55.9S — Synthetic finding at intake; repleted by twelve weeks.
Underweight (BMI 16.8) with a small appetiteactiveconfirmed R63.6S — Synthetic finding at intake.
Exacerbation of bronchiectasis (more sputum, purulent sputum, more cough and breathlessness for three days, with low-grade fever), treated with amoxicillin for 14 days and more frequent airway clearance; resolvedresolvedconfirmed J47.1S — Synthetic intercurrent exacerbation; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySputum bacterial cultureAt each review and at every exacerbation, before antibioticsCompleted todayNormal flora only; the August exacerbation sample grew Haemophilus influenzae sensitive to amoxicillin
LaboratoryC-reactive protein and white cell countAfter an exacerbationCompleted todayCRP 3.2 mg/L; white count 7.4
Self-managementAirway clearance technique and exerciseEvery visitCompleted todayTwice daily, four times a day during the exacerbation
Self-managementExacerbations: number in the past year, written plan, and rescue antibioticEvery visitCompleted todayOne in seven months, treated at home; plan renewed
Self-managementHemoptysis: amount, and when to seek emergency careEvery visitCompleted todayNone since the exacerbation
Self-managementInfluenza and pneumococcal vaccinesInfluenza yearly; pneumococcal onceCompleted todayInfluenza vaccine today; PCV20 in July
ImagingSpirometry and Bronchiectasis Severity IndexAt diagnosis, then yearlyDueAt one year
LaboratoryMycobacterial culture including nontuberculous mycobacteriaAt diagnosis (final at six to eight weeks), then yearly and with unexplained declineDueAt one year
Medication safetyOpioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goalsEvery visit, and at least every three monthsCompleted todayNo sedation; sleep and cough better; third step chosen
Medication safetyDose reduction at her request: withdrawal symptoms and sleepFour weeks after each stepCompleted todaySecond step tolerated without symptoms
Medication safetyPrescription drug monitoring program checkWith every prescription, and at least every three monthsCompleted todayOne prescriber, one pharmacy
Medication safetyNaloxone at home, and no benzodiazepines or other sedativesEvery visitCompleted todayNaloxone in date; no sedatives
SurveyPHQ-9At least monthly during active treatment (CMID)DeferredMissed: no PHQ-9 was recorded between the June visit and today, although the protocol calls for one at least monthly during active treatment. No harm judging by the PHQ-2 of 1 at the July preventive visit, the stable mood at the August sick visit, and today's PHQ-9 of 5. Corrective action: the psychologist's session scores are now entered in the chart, and a monthly PHQ-9 is sent through the patient portal
ExaminationSuicide risk review and safety planEvery visitCompleted todayNo suicidal ideation; plan kept
Self-managementGrief therapy attendance and responseWeekly for sixteen sessions, then boostersCompleted todaySixteen sessions completed and one booster
ExaminationWeight and BMIEvery visitCompleted today44.2 kg, BMI 17.9
Self-managementHepatitis B vaccineTwo doses at least four weeks apartCompleted todayDose 2 given today; series complete

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Influenza vaccine, inactivated, this season [S]

Guideline basis: British Thoracic Society Guideline for Bronchiectasis in Adults (2019); European Respiratory Society guidelines for the management of adult bronchiectasis (2017); Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR): opioid use disorder and prolonged grief disorder criteria (2022); Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Review in three months with the PHQ-9 and the opioid plan; spirometry, Bronchiectasis Severity Index, sputum and mycobacterial cultures and a urine drug test at one year; pulmonology review if exacerbations reach three a year or blood returns. [S]